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Risk factors for intensive care unit admission and 
mortality in hospitalized COVID-19 patients
Background: This study investigated the clinical features and outcome of hospitalized coro-
navirus disease 2019 (COVID-19) patients admitted to our quaternary care hospital. 
Methods: In this retrospective cohort study, we included all adult patients with COVID-19 
infection admitted to a quaternary care hospital in Pakistan from March 1 to April 15, 2020. 
The extracted variables included demographics, comorbidities, presenting symptoms, labora-
tory tests and radiological findings during admission. Outcome measures included in-hospital 
mortality and length of stay.
Results: Sixty-six COVID-19 patients were hospitalized during the study period. Sixty-one per-
cent were male and 39% female; mean age was 50.6±19.1 years. Fever and cough were the 
most common presenting symptoms. Serial chest X-rays showed bilateral pulmonary opacities 
in 33 (50%) patients. The overall mortality was 14% and mean length of stay was 8.4±8.9 
days. Ten patients (15%) required intensive care unit (ICU) care during admission, of which six 
(9%) were intubated. Age ≥60 years, diabetes, ischemic heart disease, ICU admission, neutro-
phil to lymphocyte ratio ≥3.3, and international normalized ratio ≥1.2 were associated with 
increased risk of mortality. 
Conclusions: We found a mortality rate of 14% in hospitalized COVID-19 patients. COVID-19 
cases are still increasing exponentially around the world and may overwhelm healthcare sys-
tems in many countries soon. Our findings can be used for early identification of patients 
who may require intensive care and aggressive management in order to improve outcomes.
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INTRODUCTION
Despite technological advancements in the field of medicine, humans remain vulnerable to 
emerging infectious threats. A viral pneumonia of unknown etiology that first surfaced in 
Wuhan, China has since spread rapidly across the globe. Various mitigation and suppression 
strategies for disease control have yielded mixed results. Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) has established itself as a highly adaptable pathogen that is easi-
ly transmissible, causing asymptomatic infections in a large majority of people and inflicting 
great damage when it encounters a vulnerable host [1,2]. 
 As of November 12, 2020, it had killed more than 1.3 million people and led to nearly 52 mil-
lion confirmed cases around the world [3]. Early studies revealed that the most frequent pre-
senting symptoms of this disease to be fever, cough, fatigue, sore throat and dyspnea [4]. El-
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derly patients and those with a higher comorbidity burden 
have a worse prognosis when compared to their younger and 
healthier counterparts. The former are also at a higher risk of 
developing acute respiratory distress syndrome (ARDS) and 
cytokine storm, to devastating effect [5]. To validate these 
findings, we investigated the clinical features and outcomes of 
hospitalized coronavirus disease 2019 (COVID-19) patients 
admitted to our quaternary care center. 
MATERIALS AND METHODS
Study Design/Data Source
In this retrospective cohort study, we included all adult pa-
tients with laboratory-confirmed COVID-19 infection admit-
ted to Aga Khan University Hospital from March 1 to April 15, 
2020. The study was approved by the Institutional Review 
Board of Aga Khan University (IRB No. 2020-3686-10185). 
Owing to the retrospective design, the requirement for in-
formed consent was waived.
 Patients presenting to COVID-19 screening clinics were ini-
tially evaluated by physicians and those who met the World 
Health Organization (WHO) criteria for suspected infection 
were admitted into the COVID-19 isolation ward for further 
evaluation and baseline workup. Specimens collected via na-
sopharyngeal swab were tested for COVID-19 using an reverse 
transcription polymerase chain reaction (RT-PCR) assay (Roche, 
Basel, Switzerland). These patients were managed according 
to disease severity per WHO guidelines. Patients classified as 
having severe and critical disease were managed in the inten-
sive care unit (ICU). Patients were discharged after two nega-
tive PCRs at least 24 hours apart.
 We identified these cases using the presence of an Interna-
tional Classification of Diseases (ICD-9) code for SARS-asso-
ciated Coronavirus (079.82). COVID-19 PCR results of these 
patients were then determined by the research team using an 
electronic medical record system. A confirmed case of COV-
ID-19 was defined by a positive result on RT-PCR assay of a 
specimen collected via nasopharyngeal swab. Only laborato-
ry-confirmed cases were included and analyzed. Patients who 
remained in the hospital at the time of data censoring on April 
15, 2020 were not included as their outcomes were not 
known.
Data Collection
Data was collected from the hospital’s electronic medical re-
cord system by the research team members according to a 
preapproved proforma. The data was deidentified before anal-
KEY MESSAGES 
■  Overall mortality in hospitalized coronavirus disease 
2019 (COVID-19) patients was 14% and mean length of 
stay was 8.4 ± 8.9 days. 
■  Ten patients (15%) required intensive care unit (ICU) care 
during admission, of which six (9%) were intubated. 
■  Age ≥ 60 years, diabetes, ischemic heart disease, ICU 
admission, neutrophil to lymphocyte ratio ≥ 3.3 and in-
ternational normalized ratio ≥1.2 were associated with 
increased risk of mortality. 
■  Our findings can be used for early identification of pa-
tients who may require intensive care and aggressive 
management in order to improve outcomes.
ysis. The extracted variables included demographics, comor-
bid conditions, presenting symptoms, laboratory investiga-
tions and radiological findings during the admission. Outcome 
measures included in-hospital mortality and length of stay.
Statistical Analysis
IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY) was used for 
data analysis. We used Student t-test or Wilcoxon rank-sum 
test for continuous variables, and chi-square test or Fisher ex-
act test for categorical variables, based on cell counts to deter-
mine associations between those who died and those who 
survived. We calculated odds ratios for each factor separately 
after adjusting for potential confounders such as age, sex and 
comorbid conditions. A P-value ≤ 0.05 was considered signifi-
cant.
RESULTS
Sixty-six laboratory-confirmed cases of COVID-19 were ad-
mitted to Aga Khan University Hospital during the study peri-
od. There were more males (61%) in our cohort; the mean age 
was 50.6 ± 19.1 years. Nine patients (14%) presented asymp-
tomatically, while fever (60%) was the most common present-
ing symptom. Mean time from symptom onset to presentation 
at the hospital and subsequent hospitalization was 3.8 ± 2.3 
days. Twelve patients (18%) had a recent travel history with 
the United Arab Emirates being the most frequent country of 
stay. Tables 1 and 2 detail the baseline characteristics and 
hospitalization factors of patients who died compared with 
those who survived.
 Serial chest radiography (CXR) was obtained in all patients 
and 33 (50%) showed bilateral pulmonary opacities at some 
point during their stay. The mean length of hospital stay was 
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8.4 ± 8.9 days. Twelve (18%) received a hydroxychloroquine-
azithromycin combination, 23 patients (35%) received hydroxy-
chloroquine alone and 16 (24%) received azithromycin alone. 
Hydroxychloroquine was discontinued in one patient due to 
QT prolongation. Furthermore, five patients (8%) received to-
cilizumab. Eighteen patients (27%) were started on broad spec-
trum antibiotics on suspicion of a secondary bacterial infec-
tion. Only three of the subsequent blood cultures were posi-
tive, showing Pseudomonas aeruginosa, Klebsiella pneumoniae 
and methicillin-resistant Staphylococcus aureus, respectively. 
 Non-ST elevation myocardial infarction during the hospital 
stay was observed in 5% of cases. Ten patients (15%) developed 
moderate-to-severe ARDS and were managed in the ICU with 
prone positioning and noninvasive ventilation. Six of these 
patients (9%) required mechanical ventilation due to respira-
tory failure. There were three (50%) and one (25%) deaths in 
Table 1. Demographic and clinical characteristics of COVID-19 patients 
Characteristics Overall (n=66) Expired (n=9) Survived (n=57) P-value
Mean age (yr) 50.6±19.1 74.8±9.4 46.8±17.2 <0.001
Sex 0.009
   Male 40 (61) 9 (100) 31 (54)
   Female 26 (39) 0 26 (46)
Comorbid condition
   Diabetes 25 (38) 8 (89) 17 (30) 0.001
   Hypertension 30 (46) 8 (89) 22 (39) 0.009
   Ischemic heart disease 10 (15) 6 (67) 4 (7) <0.001
   Chronic kidney Disease 3 (5) 3 (33) 0 0.002
   Asthma 2 (3) 0 2 (4) 0.999
   Malignancy 4 (6) 2 (22) 2 (4) 0.087
Presenting symptom
   Asymptomatic 9 (14) 0 9 (16) 0.341
   Fever 40 (60) 4 (44) 36 (63) 0.259
   Cough 34 (51) 4 (44) 30 (53) 0.492
   Dyspnea 15 (23) 7 (78) 8 (14) <0.001
   Sore throat 9 (14) 0 9 (16) 0.332
   Headache 5 (8) 0 5 (14) 0.999
   Nausea/vomiting 4 (6) 0 4 (7) 0.999
Hospitalization factor
   ICU admission 10 (15) 4 (44) 6 (11) 0.024
   Mechanical ventilation 6 (9) 3 (33) 3 (5) 0.029
   Length of stay 8.3±6.7 8.7±6.0 6.5±7.4 0.270
   Mean time from symptom onset to hospitalization (day) 3.8±2.3 3.3±2.7 3.9±2.3 0.954
   Mean time from symptom onset to death (day) - 9.1±9.4 - -
Treatment
   Hydroxychloroquine-azithromycin combination 12 (18) 4 (44) 8 (14) 0.055
   Hydroxychloroquine alone 23 (35) 6 (67) 17 (30) 0.055
   Azithromycin alone 16 (24) 5 (56) 11 (19) 0.032
   Tocilizumab 5 (8) 4 (44) 1 (2) 0.001
   Broad spectrum antibiotics 18 (27) 6 (67) 12 (21) 0.010
   Systemic glucocorticoids 4 (6) 1 (11) 3 (5) 0.452
Values are presented as mean±standard deviation or number (%).
COVID-19: coronavirus disease 2019; ICU: intensive care unit.
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the mechanical ventilation and noninvasive ventilation groups, 
respectively (Figure 1). The overall mortality rate was 14%. Mor-
tality in the ICU was 40% compared to 9% in the general ward. 
The five ward patients that expired had issued do-not-resusci-
tate orders. 
 Factors associated with ICU admission included diabetes, 
hypertension, ischemic heart disease, neutrophil to lympho-
cyte ratio ≥ 3.3 and international normalized ratio (INR) ≥ 1.2. 
The odds of ICU admission are presented in Table 3. Factors 
associated with mortality included age ≥ 60 years, diabetes, 
hypertension, ischemic heart disease, ICU admission, neutro-
phil to lymphocyte ratio ≥ 3.3 and INR ≥ 1.2. The odds of mor-
tality are presented in Table 4.
DISCUSSION
In this study, we present clinical characteristics and outcomes 
of 66 COVID-19 patients admitted to a quaternary care center 
in Karachi, Pakistan. Younger patients and females of all age 
groups were less likely to be hospitalized compared to males 
Table 2. Laboratory tests and radiological findings of COVID-19 
patients
Characteristics
Overall 
(n=66)
Expired 
(n=9)
Survived 
(n=57)
P-value
Chest X-ray finding 0.002
   Normal 33 (50) 0 33 (58)
   Bilateral infiltrates 33 (50) 9 (100) 24 (42)
Laboratory test
Hb (g/dl) 13.3±2.1 12.9±2.4 13.5±2.1 0.578
WBC count (×10E9/L) 9.0±7.1 11.6±4.1 8.6±7.4 0.246
Neutrophil to lym-
phocyte ratio
4.0±3.8  9.5±4.9 3.1±2.8 <0.001
Procalcitonin (ng/ml) 1.1±2.1  0.3±0.1 1.5±2.6 0.221
CRP (mg/L) 86.8±86.7 83.6±80.8 88.1±91.1 0.912
Serum lactate (mmol/L) 1.9±1.5 2.7±2.3 1.5±0.8 0.184
LDH (I.U/L)  803±1,364 569±197  949±1762 0.646
D-dimer (mg/L FEU) 2.9±5.2 3.7±7.1 2.4±3.6 0.652
Ferritin (ng/ml) 791±769 760±934 803±738 0.919
Creatinine (mg/dl) 1.1±1.2 2.4±1.5 0.9±0.8 <0.001
Total bilirubin (mg/dl) 0.7±0.4 0.8±0.4 0.7±0.5 0.820
AST (IU/L)  101±485  444±1,209 35±18 0.019
ALT (IU/L)  100±461  421±1,148 38±29 0.021
PT (sec) 11.3±1.2 12.8±1.9 10.9±0.8 <0.001
PTT (sec) 26.8±7.4 29.3±4.9 25.6±7.7 0.289
INR 1.1±0.1 1.2±0.2 1.0±0.1 <0.001
Values are presented as number (%) or mean±standard deviation.
COVID-19: coronavirus disease 2019; Hb: hemoglobin; WBC: white 
blood cells; CRP: C-reactive protein; LDH: lactate dehydrogenase; AST: 
aspartate aminotransferase; ALT: alanine transaminase; PT: prothrombin 
time; PTT: partial thromboplastin time; INR: international normalized 
ratio. 
Table 4. Adjusted odds of mortality in COVID-19 (n=66)
Characteristics
Crude 
odds
Adjusted 
odds
95% CI P-value
Age ≥60 years 22.4 20.5 2.4–177.3 0.001
Diabetes 19.2 18.8 2.2–162.4 0.001
Hypertension 12.9 12.7 1.5–108.8 0.009
Ischemic heart disease 28.6 26.5 4.7–147.8 0.001
ICU admission 15.1 14.6 2.6–80.4 0.001
Mechanical ventilation 12.4  9.0 1.4–54.9 0.029
Bilateral infiltrates on 
chest radiography
 1.5  1.4 1.1–1.7 0.002
Neutrophil to lympho-
cyte ratio ≥3.3
 1.7  1.6 1.1–2.2 0.001
INR ≥1.2  8.5  8.3 1.6–41.2 0.010
COVID-19: coronavirus disease 2019; CI: confidence interval; ICU: in-
tensive care unit; INR, international normalized ratio.
Table 3. Adjusted odds of ICU admission in COVID-19 (n=66)
Characteristics
Crude 
odds
Adjusted 
odds ratio
95% CI P-value
Diabetes   5.3   4.9 1.1–21.6 0.029
Hypertension   6.3   6.2 1.2–31.4 0.020
Ischemic heart disease   5.7   5.5 1.2–25.3 0.037
Bilateral infiltrates on chest 
radiography
14.2 12.3 1.4–101.2 0.006
Neutrophil to lymphocyte 
ratio ≥3.3
  5.6   5.2 1.2–23.1 0.029
ICU: intensive care unit; COVID-19: coronavirus disease 2019; CI: confi-
dence interval.
Figure 1. Outcomes of hospitalized coronavirus disease 2019 (CO-
VID-19) patients (n=66). ICU: intensive care unit.
10 (15%) Patients 
admitted to ICU 
56 (85%) Patients 
admitted to ward
66 COVID-19  
patients
4 (40%)  
Patients  
expired
6 (60%)  
Patients  
survived
5 (9%)  
Patients  
expired
51 (91%)  
Patients  
survived
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of older age. This is consistent with results from recent studies 
conducted in China, Italy and the United States [6-8]. Howev-
er, whether these differences are due to less exposure to the 
virus or an innate biological resistance to it remains unclear. 
 A history of recent travel from the Middle East and the Unit-
ed Kingdom was observed in 19% of our cases. Fever and cough 
were the most common initial symptoms on admission while 
11% of patients presented asymptomatically within another 
medical or surgical condition and were diagnosed on screen-
ing. Only 60% of patients with COVID-19 presented with fever, 
which is much lower than that in Wuhan (98%) and Shanghai 
(84%) [9,10]. While body temperature remains the main mon-
itoring tool for surveillance of cases, many afebrile patients in 
our population would have been missed. Our results corrobo-
rate findings from a study conducted by Mao et al. [11], which 
assessed 50,000 patients presenting to 25 fever clinics in Chi-
na, and concluded that fever was not a reliable indicator for 
COVID-19 screening.
 Chest computed tomography (CT) reveals typical radiogra-
phic features, namely ground-glass opacities and multifocal 
patchy consolidations, in almost all COVID-19 patients, even 
when COVID-19 PCR is negative [12-14]. Unfortunately, due 
to limited resources and financial constraints, chest CT was 
not performed in any of our patients during the initial weeks 
of the pandemic; CXR was used as a cheaper and more readily 
available alternative. Bilateral infiltrates were seen in exactly 
half of the patients and these findings were also significantly 
associated with a poor prognosis when compared with those 
who had normal CXR findings. The utilization of CXR instead 
of CT in COVID-19 patients’ needs to be studied further, espe-
cially in resource-restricted settings. Similarly, lung ultrasound 
is another cost-effective radiological modality that has proven 
to be extremely useful in triaging patients with suspected CO-
VID-19. It can rapidly detect extensive pulmonary involvement 
in COVID-19 patients, allowing for timely referral to the ICU if 
needed [15].
 Several therapeutic agents have been evaluated for the treat-
ment of COVID-19, but none have been established to be effi-
cacious. The usefulness of hydroxychloroquine in COVID-19 
remains inconclusive. Tang et al. [16] performed a random-
ized control trial assessing 150 patients admitted at 16 hospi-
tals in China and reported no significant improvement in clini-
cal outcomes. Adverse events were more common in hydroxy-
chloroquine recipients than in non-recipients. Our study showed 
similar results. The use of hydroxychloroquine appeared to be 
associated with poor outcomes. Remdesivir, an inhibitor of 
the viral RNA-dependent-RNA polymerase has been identi-
fied as a promising therapeutic candidate for COVID-19 be-
cause of its ability to inhibit SARS-CoV-2 in vitro. Beigel et al. 
[17] performed a randomized controlled trial that enrolled 
1,063 patients and concluded that Remdesivir was superior to 
placebo in shortening the time to recovery in hospitalized 
COVID-19 patients with evidence of respiratory tract infection.
 We found a higher mortality rate (14%) in our patients com-
pared to the rates that have been reported in other countries 
[8,10,18,19]. Many patients who were asymptomatic or had 
mild symptoms did not present to COVID-19 screening clin-
ics, and hence were not tested. Therefore, realistically, the mor-
tality rate can be presumed to be significantly lower. ICU ad-
mission and the need for mechanical ventilation in our cohort 
were reflective of disease severity; mortality was higher among 
patients who required invasive ventilation. The mortality rate 
of 40% in ICU patients is slightly lower than the rate reported 
among critically ill patients in the United States and China [6, 
20,21]. As confirmed by recent studies worldwide, male sex, 
older age and comorbid conditions were significant also risk 
factors for ICU admission and mortality in our study [22,23].
 Our study has potential limitations. Since this is a single-
center study conducted over a limited time period, the sample 
size was relatively small. Furthermore, the confidence interval 
for many factors was wide, likely due to the small number of 
patients in the study. Our results revealed an extremely high 
mortality rate in COVID-19 patients with moderate-to-severe 
disease who required hospitalization. COVID-19 cases are still 
increasing exponentially around the globe and may overwhelm 
healthcare systems in many countries. Our findings can be 
used for early identification of patients who may require in-
tensive care and aggressive management in order to improve 
outcomes.
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